Phase 1B/2 Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
Latest Information Update: 24 Nov 2023
At a glance
- Drugs Entrectinib (Primary) ; PAC 1 (Primary)
- Indications Uveal melanoma
- Focus Adverse reactions; Therapeutic Use
- 01 Nov 2023 Status changed from active, no longer recruiting to discontinued because it required dose reductions to the lower dose level (Dose level -1), but it could not be studied due to lack of funding.
- 15 Nov 2022 Planned End Date changed from 1 Jan 2024 to 1 Aug 2023.
- 15 Nov 2022 Status changed from recruiting to active, no longer recruiting.